<DOC>
	<DOCNO>NCT00509561</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin capecitabine , work different way kill tumor cell stop grow . Radiation therapy use high-energy x-ray kill tumor cell . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also stop growth tumor cell block enzymes need cell growth . It yet know whether give cisplatin together capecitabine radiation therapy effective without cetuximab treat esophageal cancer . PURPOSE : This randomized phase II/III trial study side effect well give cisplatin together capecitabine , radiation therapy , cetuximab work compare give cisplatin , capecitabine , radiation therapy without cetuximab treat patient esophageal cancer .</brief_summary>
	<brief_title>Cisplatin , Capecitabine , Radiation Therapy With Without Cetuximab Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether addition cetuximab definitive chemoradiotherapy comprise cisplatin , capecitabine , radiotherapy show evidence enhance overall survival patient carcinoma esophagus . - To determine safety regimen patient . - To determine feasibility regimen patient . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin IV 2 hour day 1 , 22 , 43 , 64 oral capecitabine twice daily day 1-84 . Beginning week 7 patient also undergo radiotherapy 5 day week 5 week ( week 7-11 ) . Treatment continue absence disease progression unacceptable toxicity . - Arm II : Patients receive cisplatin capecitabine undergo radiotherapy arm I . Patients also receive cetuximab IV 1-2 hour day 1 week 1-12 . Treatment continue absence disease progression unacceptable toxicity . Quality life health economics assess baseline , treatment , pre-specified time point follow-up . After completion study treatment , patient follow every 3 month 1 year , every 4 month 1 year , annually minimum 5 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma esophagus Adenocarcinoma Squamous cell Undifferentiated carcinoma Siewert type I tumor gastroesophageal junction Localized , nonmetastatic disease ( T14 , N01 ) confirm endoscopic ultrasound ( EUS ) spiral CT scan Total disease length ( primary lymph node ) &lt; 10 cm EUS Not suitable surgery ( either medical reason patient 's choice ) No metastatic disease ( i.e. , M1a M1b accord UICC TNM version 6 ) No significant ( &gt; 2 cm ) extension tumor stomach PATIENT CHARACTERISTICS : WHO performance status 01 Absolute neutrophil count ≥ 1,500/mm³ White blood cell count ≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL ( correct &gt; 10 g/dL treatment ) Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT/AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 3 time ULN Glomerular filtration rate &gt; 40 mL/min OR &gt; 60 mL/min estimate CockcroftGault formula Adequate cardiac ejection fraction ≥ 40 % MUGA ECHO FEV_1 ≥ 1 L spirometry Not pregnant Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year No unstable angina , uncontrolled hypertension , cardiac failure , clinically significant cardiac disease No major trauma within past 4 week No know dihydropyrimidine dehydrogenase deficiency No hearing impairment sensorymotor neuropathy &gt; grade 2 PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior sorivudine analogue At least 4 week since prior major surgery At least 4 week since prior monoclonal antibody At least 3 month since prior radiotherapy No prior treatment invasive esophageal carcinoma gastroesophageal junction carcinoma ( include photodynamic therapy laser therapy highgrade dysplasia/carcinoma situ ) No prior treatment malignancy would compromise ability deliver definitive mediastinal chemoradiotherapy compromise survival</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage IA esophageal cancer</keyword>
	<keyword>stage IB esophageal cancer</keyword>
	<keyword>stage IIA esophageal cancer</keyword>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
</DOC>